N2B Ltd. is a pharmaceutical company developing treatments for early Parkinson’s disease (PD), patients suffering from depression through the proprietary reformulation of existing drugs. N2B’s lead product is a drug-device combination of dry powder Rasagiline, which is administered via an intranasal device.
N2B is supported by the Office of the Chief Scientist (OCS) and its new executive arm, the Authority for Technological Innovation (ATI), and is on an abbreviated regulatory path for NDA and European EMA regulatory submission. The company is currently preparing its Pre Investigational New Drug (Pre-IND) Application submission to the US Food and Drug Administration, which it expects to be filed in 2017.
Curewize Health Ltd. specializes in lab tests that measure microRNA, which controls genes involved in cancer. The company has a large product pipeline, strong IP relating to cancer biomarkers and a management that is experienced in successfully developing diagnostic lab test products. Its lead product is ProALL™, a predictive assay for the therapeutic management of Acute Lymphoblastic Leukemia (ALL). Working jointly with the leading pediatric hospital, Schneider Hospital Oncology department, in Petach Tikva, Israel, the company is proceeding with the development of exciting new R&D findings on microRNA biomarkers, enabling personalized treatment of a large number of solid cancers.
Curewize is nearing the commercialization of ProALL™. The company plans to receive its CE mark in 2017 and ProALL™ is expected to be available from laboratories in the US and Europe in 2018.
BioShai Ltd. focuses on commercializing PDx™, the first blood test for diagnosing Parkinson’s disease (PD). PDx™ increases diagnostic certainty at an early stage, obviating the need to wait for disease progression. PDx™ expected to significantly improve the development of novel PD drugs, by reducing False-Positive enrolment for clinical trials. The company has been honored with an award and support from the Michael J. Fox Foundation for testing PDx™ genes in the Parkinson’s Progression Markers Initiative (PPMI) clinical study.
BioShai’s expert management has successfully commercialized lab tests. The company is nearing completion of the PDx™ development plan and expects to receive its CE mark for the PDx™ assay in 2017, after which it will initiate beta sites (final stage testing) in Israel and Italy.
GlaucoPharm Ltd. is developing a proprietary compound, TG-46. This novel topical treatment for glaucoma is based on research carried out at Bar-Ilan University in Ramat Gan, Israel. This drug works by reducing intraocular pressure (IOP), and has proven to be safe in pre-clinical trials. The company plans to demonstrate in pre-clinical tests that TG-46 has long-lasting effect on IOP elevation, in addition to neuroprotective effects.
Glaucopharm is supported by the OCS and its new executive arm, ATI. The applications of TG-46 are patent protected in the US and Europe as a prevention or treatment of intraocular hypertension and/or glaucoma, including the following: Primary Open Angle, Normal Pressure, Acute Angle Closure, Absolute Chronic, Congenital, Juvenile, Narrow Angle, Chronic Open Angle, and Simplex Glaucoma.